



Global Problem of Malaria, Biology of Malaria Parasites and Implications for Transfusion-Transmitted Malaria and Detection Methods

Sanjai Kumar, Ph.D.

Center for Biologics Research and Review


Food and Drug Administration

Malaria Workshop

July 12, 2006

Epidemiology

- *Plasmodium falciparum*, *P. vivax*, *P. ovale*, *P. malariae*
- Occurs in more than 100 countries throughout Africa, Asia, Latin America, and on certain Caribbean and Pacific Islands
- >3.2 billion inhabitants at risk
- 300 – 500 million clinical cases
- ~ 1 – 2 million per year



Representative Distributions of the Four Recognized Species of Human Malaria Parasites in the World Today

Distribution of species (%) in following areas (total no. of cases)

Species	Sub-Saharan Africa		Asia (all) (863)	Central America and Caribbean (178,242)	South America (859,480)
	West and Central (858)	East and Southern (297)			
<i>P. falciparum</i>	88.2	78.8	4.2	12.9	29.2
<i>P. vivax</i>	1.2	9.8	95.6	87.1	70.6
<i>P. malariae</i>	2.2	3.0	0.0	0.0	0.2
<i>P. ovale</i>	8.4	8.4	0.2	0.0	0.0

Global Reach of Malaria

- **In today's interconnected world, no country is immune from the hazards of malaria**
- **The problem of malaria is rising. There are more cases of malaria today than 30 years ago**
- **Major factors attributed to rise in malaria transmission**
 - **Environmental**
 - **Human activities**
 - **Drug resistance in malaria parasites**
 - **Vector populations**


Malaria Mortality: Summary Statistics at the Beginning and End of the 20th Century

Region	Year	Total no. of deaths from malaria	% of all deaths due to malaria
Europe and North America	1900	80,000	0.8
	1997	20	0.0001
Caribbean, Central and South America	1900	42,000	2
	1997	4,000	0.05
Asia, China and Western Pacific	1900	2,800,000	9
	1997	65,000	0.1
Sub-Saharan Africa	1900	210,000	6
	1997	990,000	9
World minus Sub-Saharan Africa	1900	2,900,000	8
	1997	69,000	0.08
Total World	1900	3,132,000	
	1997	1,059,020	
Total World Annual Deaths/10,000	1900	19.4	
	1997	1.84	

Malaria Incidence in India




Source: Tom Wellem, NIH




Projected Risk of Malaria Transmission in the year 2020 based on a global temperature increase of 2°F and no human efforts to contain the spread of malaria. Source: Pim Martens

<http://www.exploratorium.edu/climate/global-effects/data3.html>



**Drug resistance to *P. falciparum* from studies in sentinel sites, up to 2004.
World Malaria Report, WHO 2005.**

Malaria Life Cycle and Biology



- **Liver stage: 6 – 14 days**
- **Blood stage: 48 – 72 hrs**
- **Incubation period: 21 days**
- **Primary infections: Clinical disease of varying manifestations**
- **Adults from endemic areas develop clinical immunity but carry low-grade parasitemia**

Malaria Parasite Biology, Clinical Disease, Immunity, and implications for TTM

- **Incubation period:** Time between infection to first appearance of blood form parasites (varies between species). *P. vivax* and *P. ovale* have dormant liver form stage causing relapse infection (months to a year or more)
- **Chronicity of infection:** *P. malariae* can be present in a host for up to 40 years
- **Asymptomatic carriers:** Multiple exposures in individuals born in endemic countries or expatriates with prolonged residence develop partial immunity while carrying low-grade parasite burden
- **Parasite burden in asymptomatic carriers is not known**
- **Infectious dose of blood form malaria parasites is very low**

Donor populations that cause TTM and Implication for a Donor Screening Test

• Travelers

- No prior immunity
- Infection can be acquired shortly before departure
- Infection with a strain of Plasmodium with prolonged latency

• Residents

- Born in an endemic country or had a prolonged residence
- Asymptomatic carriers
- Parasite burden in asymptomatic carriers is not known

• History of clinical malaria

- Inadequate treatment
- Relapse from liver form parasites

Considerations for laboratory tests to detect malaria parasites in blood donors

- **Direct parasite demonstration (microscopy or DNA detection) is most suitable for all donor groups**
 - Window period of exposure in travelers before testing should be allowed and low-parasite burden in asymptomatic carriers
- **A surrogate of exposure such as the presence of anti-malaria antibodies can be indicative of a current infection or a previous exposure**
 - Time lapse between parasite exposure and first appearance of antibodies in travelers and assay sensitivity in donors with primary infections and asymptomatic carriers
 - A few reports suggest that seroconversion occurs within a few weeks after appearance of blood form parasites
- **A screening test should be able to detect all Plasmodium species that frequently cause TTM**

Methods to Detect Malaria Parasites

- Direct parasite demonstration
 - Microscopy
 - Thick blood film
 - QBC method
- Antigen detection
 - HRP, LDH etc. based dip sticks
 - Nucleic acid based methods
 - PCR test, TaqMan assay, Real-time PCR and Microarray
- Indirect demonstration of parasite exposure
 - Antibody based methods: IFAT, ELISA

THE LANCET.

A Journal of British and Foreign Medicine, Surgery, Obstetrics, Physiology,
Chemistry, Pharmacology, Public Health, and News.


IN TWO VOLUMES ANNUALLY.

VOL. I. FOR 1903.

AN IMPROVED METHOD FOR THE MICRO-
SCOPICAL DIAGNOSIS OF INTER-
MITTENT FEVER.


BY RONALD ROSS, C.B., F.R.S., F.R.C.S. ENG., D.P.H.,
LECTURER ON TROPICAL MEDICINE AT UNIVERSITY COLLEGE, LIVERPOOL;
WALTER MYERS LECTURER AT THE LIVERPOOL SCHOOL OF
TROPICAL MEDICINE; LATE MAJOR, I.M.S.

***Plasmodium falciparum*: Blood Stage Parasites Thick Blood Smears**



Sensitivity limit: 5 – 500 parasites per μL of blood. Source: CDC
http://www.dpd.cdc.gov/dpdx/HTML/ImageLibrary/Malaria_il.htm


The Quantitative Buffy Coat (QBC) Test



- A high precision glass hematocrit tube, pre-coated with acridine orange is filled with 55-65 μl of blood
- Centrifugation at 12, 000 rpm separates cells based on their densities
- Sensitivity is claimed to be as good as a thick smear

Source: <http://www.malariasite.com/malaria/QBC.htm>.

Antigen Detection Tests for Malaria




- Antigen capture by mAb or polyclonal antibody
- HRP-2, specific to Pf
- Aldolase and pLDH: pan-Plasmodium recognition
- Sensitivity: >83%
- Less sensitive in non-immune travelers
- Reactivity with auto-antibodies

Source: <http://www.malariasite.com/malaria/rdts.htm#parasight>

Nested PCR Amplification of 18 S rRNA Gene Fragment from *P. falciparum* Spiked in 1 μ L of Human Blood

Direct Boiling Method




25 5 1 .5 .25

455 bp

- 7-8 copies of 18 S rRNA
- Genus and species specific identification
- Potentially feasible for donor screening
- Sensitivity: 0.25 parasite/ μ l or 250 parasites/ml of blood
- 20-fold superior to thick blood film


Indirect Fluorescent Antibody Test




- **“Gold Standard” serology test**
- **Possible to detect all four Plasmodium species**
- **Highly effective in detecting antibodies in prior residents**
- **Cumbersome and difficult to develop an automated format**

Pan-Plasmodium reactivity of sera from malaria patients detected against individual & combination recombinant antigens in ELISA


PfCSP




PfAMA1




*PfMSP1*₄₂



*PfCSP/PfAMA1/PfMSP1*₄₂



Cross-species recognition of recombinant *P. falciparum* antigens with sera from *P. falciparum*, *P. vivax*, *P. malariae* and *P. ovale* infected patients by western blot



Lanes 1: *rPfCSP*, 2: *rPfAMA-1*, 3: *rPfMSP1*₄₂

Acknowledgements

- **CBER**

Hong Zheng

Babita Mahajan

Hira L. Nakhasi

- **WRAIR**

David Haynes

- **CDC**

Monica Parise

Marriana Wilson

- **NIAID**

Malaria Vaccine Development Branch